3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 4
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Conditions
Motor Activity
1
Melanoma
1
Interventions
Cisplatin
1041
Cyclophosphamide
973
Carboplatin
954
Radiotherapy
893
Bevacizumab
847
Gemcitabine
817
pembrolizumab
759
Paclitaxel
738
Docetaxel
734
Oxaliplatin
706
Capecitabine
649
Fluorouracil
564
Rituximab
559
Nivolumab
506
Dexamethasone
487
Etoposide
468
Doxorubicin
458
Irinotecan
442
Drug Therapy
402
Leucovorin
377
Cytarabine
342
Cetuximab
340
Lenalidomide
326
Trastuzumab
323
Pemetrexed
315
durvalumab
295
Filgrastim
287
Magnetic Resonance Spectroscopy
278
Temozolomide
275
Prednisone
274
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
Clinical Trials as Topic
×
Clear all
NCT02645149
2026-05-29
Match Mel
Melanoma Institute Australia
Phase 2
Completed
216 enrolled
NCT01571401
2013-06-19
TRACKS
University of Alberta
Phase 2
Completed
32 enrolled